Fecal microbiota transplantation: current challenges and future landscapes
Abbas Yadegar,Haggai Bar-Yoseph,Tanya Marie Monaghan,Sepideh Pakpour,Andrea Severino,Ed J. Kuijper,Wiep Klaas Smits,Elisabeth M. Terveer,Sukanya Neupane,Ali Nabavi-Rad,Javad Sadeghi,Giovanni Cammarota,Gianluca Ianiro,Estello Nap-Hill,Dickson Leung,Karen Wong,Dina Kao
DOI: https://doi.org/10.1128/cmr.00060-22
IF: 36.8
2024-05-09
Clinical Microbiology Reviews
Abstract:SUMMARY Given the importance of gut microbial homeostasis in maintaining health, there has been considerable interest in developing innovative therapeutic strategies for restoring gut microbiota. One such approach, fecal microbiota transplantation (FMT), is the main “whole gut microbiome replacement” strategy and has been integrated into clinical practice guidelines for treating recurrent Clostridioides difficile infection (rCDI). Furthermore, the potential application of FMT in other indications such as inflammatory bowel disease (IBD), metabolic syndrome, and solid tumor malignancies is an area of intense interest and active research. However, the complex and variable nature of FMT makes it challenging to address its precise functionality and to assess clinical efficacy and safety in different disease contexts. In this review, we outline clinical applications, efficacy, durability, and safety of FMT and provide a comprehensive assessment of its procedural and administration aspects. The clinical applications of FMT in children and cancer immunotherapy are also described. We focus on data from human studies in IBD in contrast with rCDI to delineate the putative mechanisms of this treatment in IBD as a model, including colonization resistance and functional restoration through bacterial engraftment, modulating effects of virome/phageome, gut metabolome and host interactions, and immunoregulatory actions of FMT. Furthermore, we comprehensively review omics technologies, metagenomic approaches, and bioinformatics pipelines to characterize complex microbial communities and discuss their limitations. FMT regulatory challenges, ethical considerations, and pharmacomicrobiomics are also highlighted to shed light on future development of tailored microbiome-based therapeutics.
microbiology